Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Temozolomide SCHEMBL3270220 | 0.88 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3739 | 0.88 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL28275477 | 0.87 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.87 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.87 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.87 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL27721442 | 0.86 | MEN1 (0.89) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL892333 | 0.80 | MEN1 (0.78) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL16227379 | 0.80 | MEN1 (0.82) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL10168201 | 0.79 | MEN1 (0.81) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3982977-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | Children's Medical Research Institute (AU) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020248018-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2020-12-17 | — | — | WO | disclosed |
| US-10669260-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| CN-110461315-A | Treatment and Prevention of Cytokine Release Syndrome Using Chimeric Antigen Receptors in Combination with Kinase Inhibitors | NOVARTIS AG | 2019-11-15 | — | — | CN | disclosed |
| CN-108700590-A | Cell population analysis | 英国质谱公司 | 2018-10-23 | — | — | CN | disclosed |
| US-20180065952-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2018-03-08 | — | — | US | disclosed |
| CN-107667288-A | Spectral analysis of microorganisms | 英国质谱公司 | 2018-02-06 | — | — | CN | disclosed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065952-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | IKZF3, IKZF1, APC | MEN1 3927/4885PABPC1 2075/4885KMT2A 4004/4885 |
| US-10669260-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | IKZF3, IKZF1, APC | MEN1 3927/4885PABPC1 2075/4885KMT2A 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.